A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Recombinant Human Relaxin (rhRlx) in Subjects With Severe Preeclampsia.
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2013
At a glance
- Drugs Serelaxin (Primary)
- Indications Preeclampsia
- Focus Adverse reactions
- 24 Mar 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 05 Dec 2006 Status change
- 29 Sep 2006 New trial record.